Retrospective cohort study observes 80–82% virological suppression in people living with HIV on dolutegravir-based therapy, indicating high real-world efficacy for regimen transitions.
In a retrospective Nigerian cohort of 33,982 PLHIV initiating or switching to TLD, virological suppression reached 80–82% among participants with available viral load data and 63–65% by intention-to-treat analysis. Suppression was higher among switchers, while age and gender predicted suppression.
No takes yet. Share an insight, caveat, or question.
Abdullahi et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: